Tag: KDC-MN-1598

  • Mirogabalin

    Selective alpha-2-delta-1 subunit ligand of voltage-gated calcium channels (gabapentinoid)

    A next-generation gabapentinoid developed by Daiichi Sankyo with preferential binding and prolonged dissociation kinetics at the alpha-2-delta-1 subunit of voltage-gated calcium channels, approved in Japan and select Asian jurisdictions for peripheral neuropathic pain and distinguished from pregabalin and gabapentin by subunit selectivity and a potentially wider therapeutic margin.

    Abstract

    Mirogabalin (DS-5565) is a novel gabapentinoid analgesic that binds with high affinity and selectivity to the alpha-2-delta-1 (alpha2delta-1) subunit of voltage-gated calcium channels (VGCCs), developed by Daiichi Sankyo Company and approved in Japan in January 2019 for the treatment of peripheral neuropathic pain associated with diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN). The compound is marketed as Tarlige in oral tablet formulation and has subsequently received regulatory approval in Taiwan (2020) and Thailand (2022) for peripheral neuropathic pain indications. Unlike the first-generation gabapentinoids gabapentin and pregabalin, which bind nonselectively to both alpha2delta-1 and alpha2delta-2 subunits with comparable affinity and dissociation kinetics, mirogabalin demonstrates preferential binding to the alpha2delta-1 subunit with a dissociation half-life of approximately 11.1 hours at alpha2delta-1 versus 2.4 hours at alpha2delta-2 in human recombinant systems. This kinetic selectivity is hypothesized to confer a favorable ratio of analgesic efficacy (mediated principally through alpha2delta-1 in dorsal root ganglia and spinal cord dorsal horn) to central nervous system adverse effects (mediated in part through alpha2delta-2 in cerebellar Purkinje neurons and other central structures), although this hypothesis has not been formally validated in controlled comparative clinical trials against pregabalin at equipotent analgesic doses.

    A separate Phase 3 program evaluated mirogabalin for central neuropathic pain after spinal cord injury in a multinational Asian trial. In contrast, the global Phase 3 ALDAY program for fibromyalgia pain, consisting of three large randomized trials enrolling more than 3,600 subjects in the United States and Europe, failed to meet the primary efficacy endpoint in all three studies; mirogabalin did not demonstrate statistically significant superiority over placebo for reduction in worst daily pain score at week 13 in fibromyalgia, and the fibromyalgia development program was subsequently discontinued. The compound is not approved by the United States Food and Drug Administration or the European Medicines Agency.

    Pharmacokinetically, mirogabalin is rapidly and nearly completely absorbed after oral administration with a time to peak plasma concentration of approximately 1 hour. The compound undergoes limited hepatic metabolism (13 to 20 percent of administered dose) through uridine 5-prime-diphospho-glucuronosyltransferase (UGT) isoforms, with the majority of the dose (61 to 72 percent) excreted unchanged in urine. Renal clearance exceeds glomerular filtration rate, indicating active tubular secretion. Dose adjustment is required in patients with renal impairment. The principal adverse events are somnolence, dizziness, peripheral edema, and weight gain, consistent with the gabapentinoid class but reported at generally lower incidence than pregabalin at comparable analgesic doses in some observational comparisons.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.